INBX logo

Inhibrx Biosciences, Inc. (INBX) EBIT

Annual EBIT:

-$331.45M-$178.70M(-116.99%)
December 31, 2024

Summary

  • As of today, INBX annual earnings before interest & taxes is -$331.45 million, with the most recent change of -$178.70 million (-116.99%) on December 31, 2024.
  • During the last 3 years, INBX annual EBIT has fallen by -$254.90 million (-332.98%).
  • INBX annual EBIT is now -1582.14% below its all-time high of -$19.70 million, reached on December 31, 2017.

Performance

INBX EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherINBXincome statement metrics

Quarterly EBIT:

-$33.81M-$6.42M(-23.45%)
September 30, 2025

Summary

  • As of today, INBX quarterly earnings before interest & taxes is -$33.81 million, with the most recent change of -$6.42 million (-23.45%) on September 30, 2025.
  • Over the past year, INBX quarterly EBIT has increased by +$12.98 million (+27.75%).
  • INBX quarterly EBIT is now -839.22% below its all-time high of -$3.60 million, reached on March 31, 2019.

Performance

INBX Quarterly EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherINBXincome statement metrics

TTM EBIT:

-$154.03M+$12.98M(+7.77%)
September 30, 2025

Summary

  • As of today, INBX TTM earnings before interest & taxes is -$154.03 million, with the most recent change of +$12.98 million (+7.77%) on September 30, 2025.
  • Over the past year, INBX TTM EBIT has increased by +$127.49 million (+45.29%).
  • INBX TTM EBIT is now -1636.72% below its all-time high of -$8.87 million, reached on March 31, 2018.

Performance

INBX TTM EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherINBXincome statement metrics

EBIT Formula

EBIT = Revenue − COGS − Operating Expenses

INBX EBIT Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year-117.0%+27.8%+45.3%
3Y3 Years-333.0%-13.6%-36.7%
5Y5 Years-640.1%-117.0%-149.7%

INBX EBIT Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-333.0%at low-23.4%+79.0%-36.7%+53.5%
5Y5-Year-640.1%at low-117.0%+79.0%-149.7%+53.5%
All-TimeAll-Time-1582.1%at low-839.2%+79.0%-1636.7%+53.5%

INBX EBIT History

DateAnnualQuarterlyTTM
Sep 2025
-
-$33.81M(-23.5%)
-$154.03M(+7.8%)
Jun 2025
-
-$27.39M(+36.2%)
-$167.01M(+44.4%)
Mar 2025
-
-$42.90M(+14.1%)
-$300.52M(+9.3%)
Dec 2024
-$331.45M(-117.0%)
-$49.93M(-6.7%)
-$331.45M(-17.7%)
Sep 2024
-
-$46.80M(+70.9%)
-$281.52M(-19.9%)
Jun 2024
-
-$160.90M(-117.9%)
-$234.72M(-103.8%)
Mar 2024
-
-$73.83M(-78.6%)
-$115.16M(+22.5%)
Dec 2023
-$152.75M(-32.5%)
-
-
Jun 2023
-
-$41.34M(+5.5%)
-$148.69M(-4.8%)
Mar 2023
-
-$43.77M(-29.5%)
-$141.87M(-11.6%)
Dec 2022
-$115.32M(-50.7%)
-$33.80M(-13.5%)
-$127.09M(-12.8%)
Sep 2022
-
-$29.78M(+13.8%)
-$112.69M(-10.8%)
Jun 2022
-
-$34.53M(-19.1%)
-$101.72M(-16.9%)
Mar 2022
-
-$28.98M(-49.3%)
-$86.99M(-13.6%)
Dec 2021
-$76.55M
-$19.41M(-3.2%)
-$76.55M(-3.1%)
DateAnnualQuarterlyTTM
Sep 2021
-
-$18.80M(+5.0%)
-$74.25M(-4.5%)
Jun 2021
-
-$19.80M(-6.8%)
-$71.03M(-8.1%)
Mar 2021
-
-$18.54M(-8.3%)
-$65.72M(-1.4%)
Dec 2020
-$64.82M(-44.7%)
-$17.11M(-9.8%)
-$64.82M(-5.1%)
Sep 2020
-
-$15.58M(-7.6%)
-$61.70M(+1.6%)
Jun 2020
-
-$14.48M(+17.9%)
-$62.71M(-6.6%)
Mar 2020
-
-$17.64M(-26.1%)
-$58.83M(-31.4%)
Dec 2019
-$44.78M(-52.1%)
-$13.99M(+15.7%)
-$44.78M(-45.4%)
Sep 2019
-
-$16.59M(-56.6%)
-$30.79M(-116.9%)
Jun 2019
-
-$10.60M(-194.4%)
-$14.20M(-38.4%)
Mar 2019
-
-$3.60M(+46.0%)
-$10.26M(+33.9%)
Dec 2018
-$29.45M(-49.4%)
-
-
Jun 2018
-
-$6.66M(+24.9%)
-$15.53M(-75.1%)
Mar 2018
-
-$8.87M
-$8.87M
Dec 2017
-$19.70M
-
-

FAQ

  • What is Inhibrx Biosciences, Inc. annual earnings before interest & taxes?
  • What is the all-time high annual EBIT for Inhibrx Biosciences, Inc.?
  • What is Inhibrx Biosciences, Inc. annual EBIT year-on-year change?
  • What is Inhibrx Biosciences, Inc. quarterly earnings before interest & taxes?
  • What is the all-time high quarterly EBIT for Inhibrx Biosciences, Inc.?
  • What is Inhibrx Biosciences, Inc. quarterly EBIT year-on-year change?
  • What is Inhibrx Biosciences, Inc. TTM earnings before interest & taxes?
  • What is the all-time high TTM EBIT for Inhibrx Biosciences, Inc.?
  • What is Inhibrx Biosciences, Inc. TTM EBIT year-on-year change?

What is Inhibrx Biosciences, Inc. annual earnings before interest & taxes?

The current annual EBIT of INBX is -$331.45M

What is the all-time high annual EBIT for Inhibrx Biosciences, Inc.?

Inhibrx Biosciences, Inc. all-time high annual earnings before interest & taxes is -$19.70M

What is Inhibrx Biosciences, Inc. annual EBIT year-on-year change?

Over the past year, INBX annual earnings before interest & taxes has changed by -$178.70M (-116.99%)

What is Inhibrx Biosciences, Inc. quarterly earnings before interest & taxes?

The current quarterly EBIT of INBX is -$33.81M

What is the all-time high quarterly EBIT for Inhibrx Biosciences, Inc.?

Inhibrx Biosciences, Inc. all-time high quarterly earnings before interest & taxes is -$3.60M

What is Inhibrx Biosciences, Inc. quarterly EBIT year-on-year change?

Over the past year, INBX quarterly earnings before interest & taxes has changed by +$12.98M (+27.75%)

What is Inhibrx Biosciences, Inc. TTM earnings before interest & taxes?

The current TTM EBIT of INBX is -$154.03M

What is the all-time high TTM EBIT for Inhibrx Biosciences, Inc.?

Inhibrx Biosciences, Inc. all-time high TTM earnings before interest & taxes is -$8.87M

What is Inhibrx Biosciences, Inc. TTM EBIT year-on-year change?

Over the past year, INBX TTM earnings before interest & taxes has changed by +$127.49M (+45.29%)
On this page